Sugi Predict

Sugi Predict / Compounds / SCHEMBL547192

SCHEMBL547192

SCHEMBL547192

O=C(O)CCCCN1CCCCC1

nearest known ligand 0.88

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ CYP1A2 P05177 1/20 0.88
▸ MAPK1 P28482 1/20 0.88
▸ SMN1; SMN2 Q16637 1/20 0.88
▸ HRH3 Q9Y5N1 1/20 0.58
▸ ALDH1A1 P00352 4/20 0.56
▸ MAPT P10636 3/20 0.56
▸ ALOX15 P16050 1/20 0.56
▸ POLB P06746 1/20 0.54
▸ L3MBTL1 Q9Y468 1/20 0.52
▸ HTR7 P34969 5/20 0.49
▸ LMNA P02545 2/20 0.48
▸ TSHR P16473 1/20 0.46
▸ NFKB1 P19838 1/20 0.46
▸ PMP22 Q01453 1/20 0.46
▸ KMT2A Q03164 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2639576 1.00 CYP1A2 (0.88) CYP1A2MAPK1SMN1; SMN2HRH3ALDH1A1
SCHEMBL6092611 0.98 CYP1A2 (0.84) CYP1A2MAPK1SMN1; SMN2HRH3ALDH1A1
SCHEMBL7364534 0.98 CYP1A2 (0.84) CYP1A2MAPK1SMN1; SMN2HRH3ALDH1A1
SCHEMBL26495548 0.98 CYP1A2 (0.84) CYP1A2MAPK1SMN1; SMN2HRH3ALDH1A1
SCHEMBL10448990 0.98 CYP1A2 (0.84) CYP1A2MAPK1SMN1; SMN2HRH3ALDH1A1
SCHEMBL27033239 0.98 CYP1A2 (0.84) CYP1A2MAPK1SMN1; SMN2HRH3ALDH1A1
Hydrochloric Acid SCHEMBL3810610 0.98 CYP1A2 (0.84) CYP1A2MAPK1SMN1; SMN2HRH3ALDH1A1
SCHEMBL26495605 0.98 CYP1A2 (0.84) CYP1A2MAPK1SMN1; SMN2HRH3ALDH1A1
SCHEMBL1856267 0.98 CYP1A2 (0.83) CYP1A2MAPK1SMN1; SMN2HRH3ALDH1A1
Hydrochloric Acid SCHEMBL18939455 0.96 CYP1A2 (0.80) CYP1A2MAPK1SMN1; SMN2HRH3ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 116 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2968145-A1 MODIFIED DOCETAXEL LIPOSOME FORMULATIONS Mallinckrodt LLC (US) 2016-01-20 — — EP claimed
CN-105188675-A Modified docetaxel liposome formulations MALLINCKRODT LLC 2015-12-23 — — CN claimed
CN-103242694-B Low-odor environment-friendly nano pigment ink-jet ink composition JETBEST CORP. (CN) 2014-10-29 — — CN claimed
WO-2014160392-A1 MODIFIED DOCETAXEL LIPOSOME FORMULATIONS MALLINCKRODT LLC (US) 2014-10-02 — — WO claimed
CN-103242694-A Low-odor environment-friendly nano pigment ink-jet ink composition JETBEST CORP 2013-08-14 — — CN claimed
JP-2011528372-A — — 2011-11-17 — — JP claimed
US-20100130474-A1 ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR INHIBITORS WYETH (US) 2010-05-27 — — US claimed
WO-2010009290-A1 ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR INHIBITORS WYETH (US) 2010-01-21 — — WO claimed
US-6753409-B1 FOR TREATMENT OF MYOCARDIAL INFARCTION, STROKE, PERIPHERAL ARTERIAL DISEASE AND DISSEMINATED INTRAVASCULAR COAGULATION AVENTIS PHARMACEUTICALS INC. 2004-06-22 — — US claimed
EP-0923553-A4 STABLE NON-HYGROSCOPIC CRYSTALLINE FORM OF N- N-N-(4-(PIPERIDIN-4-YL)BUTANOYL)-N-ETHYLGLYCYL] COMPOUNDS RHONE POULENC RORER PHARMA (US) 1999-12-08 — — EP claimed
EP-0923553-A1 STABLE NON-HYGROSCOPIC CRYSTALLINE FORM OF N- N-N-(4-(PIPERIDIN-4-YL)BUTANOYL)-N-ETHYLGLYCYL] COMPOUNDS RHONE-POULENC RORER PHARMACEUTICALS, INC. (US) 1999-06-23 — — EP claimed
WO-1998007696-A1 STABLE NON-HYGROSCOPIC CRYSTALLINE FORM OF N-[N-N-(4-(PIPERIDIN-4-YL)BUTANOYL)-N-ETHYLGLYCYL] COMPOUNDS RHONE-POULENC RORER PHARMACEUTICALS INC. (US) 1998-02-26 — — WO claimed
US-12582641-B2 Sulfur-containing compound based on glutarimide skeleton and application thereof SHANGHAITECH UNIVERSITY (CN) 2026-03-24 — — US disclosed
US-20250082559-A1 EXTERNAL-USE SKIN PREPARATION COMPOSITION SHISEIDO COMPANY, LTD. (JP) 2025-03-13 — — US disclosed
US-20250041188-A1 COSMETIC SHISEIDO COMPANY, LTD. (JP) 2025-02-06 — — US disclosed
US-20240423890-A1 COSMETIC SHISEIDO COMPANY, LTD. (JP) 2024-12-26 — — US disclosed
WO-1998007696-A1 STABLE NON-HYGROSCOPIC CRYSTALLINE FORM OF N-[N-N-(4-(PIPERIDIN-4-YL)BUTANOYL)-N-ETHYLGLYCYL] COMPOUNDS RHONE-POULENC RORER PHARMACEUTICALS INC. (US) 1998-02-26 — — WO disclosed
CN-1124485-A Novel 1-phenylalkanone 5-HT4Receptor ligands SYNTEX A INC (US) 1996-06-12 — — CN disclosed
EP-0700383-A1 NOVEL 1-PHENYLALKANONE 5-HT 4? RECEPTOR LIGANDS SYNTEX (U.S.A.) INC. (US) 1996-03-13 — — EP disclosed
WO-1994027965-A1 NOVEL 1-PHENYLALKANONE 5-HT4 RECEPTOR LIGANDS SYNTEX (U.S.A.) INC. (US) 1994-12-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12582641-B2 Sulfur-containing compound based on glutarimide skeleton and application thereof SUCNR1, SRD5A1, GLS CYP1A2 2225/4885MAPK1 1912/4885SMN1; SMN2 441/4885
US-20250041188-A1 COSMETIC GLA, ASAH2, SORD CYP1A2 3209/4885MAPK1 3820/4885SMN1; SMN2 1347/4885
US-20250082559-A1 EXTERNAL-USE SKIN PREPARATION COMPOSITION TYR, CUTA, NACA CYP1A2 302/4885MAPK1 2544/4885SMN1; SMN2 4414/4885
US-20240423890-A1 COSMETIC TYR, RBP1, NISCH CYP1A2 1217/4885MAPK1 1932/4885SMN1; SMN2 4760/4885
US-20100130474-A1 ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR INHIBITORS CHRNA7, CHRNA6, CHRNA2 CYP1A2 2584/4885MAPK1 1513/4885SMN1; SMN2 1693/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.